Core Viewpoint - The article emphasizes the importance of timing and sustainability in stock trends for successful short-term investing, highlighting that sound fundamentals and positive earnings revisions are crucial for maintaining momentum in stock prices [1][2]. Group 1: Stock Performance - KB Financial has shown a solid price increase of 47.2% over the past 12 weeks, indicating strong investor interest and potential upside [4]. - The stock has also increased by 9.3% in the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, KB Financial is trading at 91.2% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - KB Financial holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for investors to identify stocks like KB Financial that are on an uptrend supported by strong fundamentals [3]. - The article suggests that there are several other stocks passing through this screen, providing additional investment opportunities for trend-focused investors [8].

Earnings Performance - Commercial Metals (CMC) reported quarterly earnings of $0.74 per share, missing the Zacks Consensus Estimate of $0.85 per share, and down from $1.02 per share a year ago [1] - The earnings surprise was -12.94%, and the company has not surpassed consensus EPS estimates over the last four quarters [2] - The company posted revenues of $2.02 billion for the quarter, surpassing the Zacks Consensus Estimate by 0.49%, but down from $2.08 billion year-over-year [3] Stock Performance - Commercial Metals shares have declined approximately 1.9% since the beginning of the year, while the S&P 500 has gained 1.5% [4] - The current Zacks Rank for the stock is 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.12 on revenues of $2.09 billion, and for the current fiscal year, it is $3.02 on revenues of $7.76 billion [8] - The outlook for the Steel - Producers industry is positive, ranking in the top 34% of over 250 Zacks industries, suggesting potential for outperformance [9]

Core Viewpoint - HubSpot (HUBS) has experienced significant selling pressure, declining 13.3% over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that helps identify whether a stock is oversold, with readings below 30 indicating oversold conditions [2] - HUBS has an RSI reading of 22.07, suggesting that heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5] Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts to raise earnings estimates for HUBS, with a 0.4% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7] - HUBS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8]

Group 1: Earnings Performance - CarMax reported quarterly earnings of $1.38 per share, exceeding the Zacks Consensus Estimate of $1.18 per share, and up from $0.97 per share a year ago, representing an earnings surprise of 16.95% [1] - The company posted revenues of $7.55 billion for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 0.40%, compared to year-ago revenues of $7.11 billion [2] - Over the last four quarters, CarMax has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - CarMax shares have declined approximately 21.3% since the beginning of the year, while the S&P 500 has gained 1.7% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $1.06 on revenues of $7.22 billion, and $3.76 on revenues of $27.53 billion for the current fiscal year [7] Group 3: Industry Context - The Automotive - Retail and Wholesale - Parts industry, to which CarMax belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact CarMax's stock performance [5][6]

Core Viewpoint - Plus Therapeutics (PSTV) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the correlation between changes in earnings estimates and stock price movements, making it a valuable tool for investors [2][3]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to price movements based on their buying or selling activities [3]. Company Performance Indicators - The upgrade for Plus reflects an improvement in the company's underlying business, which is expected to positively influence its stock price [4]. - Over the past three months, the Zacks Consensus Estimate for Plus has increased by 78.7%, indicating a significant upward revision in earnings expectations [7]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6]. - Plus's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Group 1 - Arcosa (ACA) closed at $87.00, with a 2.1% gain over the past four weeks, and a mean price target of $109.2 indicating a 25.5% upside potential [1] - The average price target ranges from a low of $100.00 to a high of $120.00, with a standard deviation of $7.29, suggesting a 14.9% to 37.9% upside [2] - Analysts show strong agreement on ACA's ability to report better earnings, with positive trends in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for ACA has increased by 1.1% due to one upward revision in earnings estimates over the last 30 days [12] - ACA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate potential price movement direction [14]

A downtrend has been apparent in Paycom Software (PAYC) lately with too much selling pressure. The stock has declined 9.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversol ...

Core Viewpoint - Intellicheck Mobilisa, Inc. (IDN) shows potential as a stock pick due to its recent technical performance, surpassing resistance levels and indicating a bullish trend [1]. Technical Analysis - IDN has recently moved above its 20-day simple moving average, which is a positive indicator for short-term traders as it suggests a bullish trend [2]. - The stock has increased by 24.1% over the past four weeks, reinforcing the positive technical outlook [4]. Earnings Estimates - There have been two upward revisions in IDN's earnings estimates for the current fiscal year, with no downward revisions, indicating strong investor confidence [4]. - The consensus earnings estimate has also increased, further supporting the bullish sentiment around IDN [4][5].

NovoCure (NVCR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual ...

Core Viewpoint - Senseonics Holdings (SENS) has experienced significant selling pressure, resulting in a 5.7% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with a reading below 30 indicating oversold conditions [2] - SENS has an RSI reading of 23.99, suggesting that the heavy selling may be exhausting, indicating a potential rebound towards equilibrium [5] Fundamental Indicators - There is a strong consensus among sell-side analysts to raise earnings estimates for SENS, leading to a 26.3% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7] - SENS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]